Cargando…
Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients
INTRODUCTION: CD155 is an immune checkpoint protein. Its overexpression is an indicator of poor prognosis in some types of cancer. However, the significance of CD155 expression in patients with triple-negative breast cancer, and the relationship between CD155 and programmed death-ligand 1 (PD-L1) ex...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195407/ https://www.ncbi.nlm.nih.gov/pubmed/34115802 http://dx.doi.org/10.1371/journal.pone.0253176 |
_version_ | 1783706496336396288 |
---|---|
author | Yoshikawa, Katsuhiro Ishida, Mitsuaki Yanai, Hirotsugu Tsuta, Koji Sekimoto, Mitsugu Sugie, Tomoharu |
author_facet | Yoshikawa, Katsuhiro Ishida, Mitsuaki Yanai, Hirotsugu Tsuta, Koji Sekimoto, Mitsugu Sugie, Tomoharu |
author_sort | Yoshikawa, Katsuhiro |
collection | PubMed |
description | INTRODUCTION: CD155 is an immune checkpoint protein. Its overexpression is an indicator of poor prognosis in some types of cancer. However, the significance of CD155 expression in patients with triple-negative breast cancer, and the relationship between CD155 and programmed death-ligand 1 (PD-L1) expression, have not yet been analyzed in detail. METHODS: Using immunohistochemical staining and tissue microarrays, we analyzed the expression profiles of CD155 and PD-L1 in 61 patients with triple-negative breast cancer. Relapse-free survival and overall survival rates were compared according to CD155 expression. The correlation between CD155 expression and clinicopathological factors, including PD-L1 expression (using SP142 and 73–10 assays), was also examined. RESULTS: CD155 expression was noted in 25 patients (41.0%) in this cohort. CD155 expression did not correlate with pathological stage, histological grade, Ki-67 labeling index, or stromal tumor-infiltrating lymphocytes. Only PD-L1 expression in tumor cells by SP142 assay significantly correlated with CD155 expression (p = 0.035); however, PD-L1 expression in tumor cells by 73–10 assay did not show a correlation (p = 0.115). Using the 73–10 assay, 59% of patients showed CD155 and/or PD-L1 expression in tumor cells. Moreover, using the SP142 assay, 63.3% of patients showed CD155 and/or PD-L1 expression in immune cells. CD155 expression did not correlate with either relapse-free survival or overall survival (p = 0.485 and 0.843, respectively). CONCLUSIONS: CD155 may be a novel target for antitumor immunotherapy. The results of this study indicate that CD155 may expand the pool of candidates with triple-negative breast cancer who could benefit from antitumor immunotherapy. |
format | Online Article Text |
id | pubmed-8195407 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-81954072021-06-21 Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients Yoshikawa, Katsuhiro Ishida, Mitsuaki Yanai, Hirotsugu Tsuta, Koji Sekimoto, Mitsugu Sugie, Tomoharu PLoS One Research Article INTRODUCTION: CD155 is an immune checkpoint protein. Its overexpression is an indicator of poor prognosis in some types of cancer. However, the significance of CD155 expression in patients with triple-negative breast cancer, and the relationship between CD155 and programmed death-ligand 1 (PD-L1) expression, have not yet been analyzed in detail. METHODS: Using immunohistochemical staining and tissue microarrays, we analyzed the expression profiles of CD155 and PD-L1 in 61 patients with triple-negative breast cancer. Relapse-free survival and overall survival rates were compared according to CD155 expression. The correlation between CD155 expression and clinicopathological factors, including PD-L1 expression (using SP142 and 73–10 assays), was also examined. RESULTS: CD155 expression was noted in 25 patients (41.0%) in this cohort. CD155 expression did not correlate with pathological stage, histological grade, Ki-67 labeling index, or stromal tumor-infiltrating lymphocytes. Only PD-L1 expression in tumor cells by SP142 assay significantly correlated with CD155 expression (p = 0.035); however, PD-L1 expression in tumor cells by 73–10 assay did not show a correlation (p = 0.115). Using the 73–10 assay, 59% of patients showed CD155 and/or PD-L1 expression in tumor cells. Moreover, using the SP142 assay, 63.3% of patients showed CD155 and/or PD-L1 expression in immune cells. CD155 expression did not correlate with either relapse-free survival or overall survival (p = 0.485 and 0.843, respectively). CONCLUSIONS: CD155 may be a novel target for antitumor immunotherapy. The results of this study indicate that CD155 may expand the pool of candidates with triple-negative breast cancer who could benefit from antitumor immunotherapy. Public Library of Science 2021-06-11 /pmc/articles/PMC8195407/ /pubmed/34115802 http://dx.doi.org/10.1371/journal.pone.0253176 Text en © 2021 Yoshikawa et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Yoshikawa, Katsuhiro Ishida, Mitsuaki Yanai, Hirotsugu Tsuta, Koji Sekimoto, Mitsugu Sugie, Tomoharu Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients |
title | Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients |
title_full | Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients |
title_fullStr | Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients |
title_full_unstemmed | Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients |
title_short | Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients |
title_sort | immunohistochemical analysis of cd155 expression in triple-negative breast cancer patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195407/ https://www.ncbi.nlm.nih.gov/pubmed/34115802 http://dx.doi.org/10.1371/journal.pone.0253176 |
work_keys_str_mv | AT yoshikawakatsuhiro immunohistochemicalanalysisofcd155expressionintriplenegativebreastcancerpatients AT ishidamitsuaki immunohistochemicalanalysisofcd155expressionintriplenegativebreastcancerpatients AT yanaihirotsugu immunohistochemicalanalysisofcd155expressionintriplenegativebreastcancerpatients AT tsutakoji immunohistochemicalanalysisofcd155expressionintriplenegativebreastcancerpatients AT sekimotomitsugu immunohistochemicalanalysisofcd155expressionintriplenegativebreastcancerpatients AT sugietomoharu immunohistochemicalanalysisofcd155expressionintriplenegativebreastcancerpatients |